US FDA Approves Rasonque, First Drug Targeting Key Pancreatic Cancer Mutation
The US Food and Drug Administration has approved Rasonque (daraxonrasib), the first drug targeting the molecular cause of most pancreatic cancers. Clinical trials showed it nearly doubled median survival to 13.2 months from 6.7 months compared to standard chemotherapy. Approved for adults with metastatic pancreatic ductal adenocarcinoma who have had prior systemic therapy or cannot tolerate chemotherapy, Rasonque blocks the RAS protein, a key driver in over 90% of these cancers. Side effects include rash and mouth sores.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 44/100.
Outlets measured: hindustantimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 26 Aug, 04:27 pm. Other outlets followed.